No Published Results Available for BMS-986460 (NCT06067841)
There are currently no published results for the BMS-986460 trial (NCT06067841) in men with metastatic castration-resistant prostate cancer. The evidence provided contains information about a different BMS compound (BMS-986365/CC-94676), which is an androgen receptor ligand-directed degrader, but this is not the same agent as BMS-986460.
What We Know About BMS-986365 (Different Trial)
The available research evidence describes BMS-986365 (CC-94676), tested in the CC-94676-PCA-001 trial (NCT04428788), not BMS-986460 1. This is a distinct compound with different mechanisms and trial identifiers.
BMS-986365 Trial Results (For Context Only)
For BMS-986365 in heavily pretreated mCRPC patients 1:
- PSA50 response: 32% overall at highest doses (400-900 mg twice daily); 50% at 900 mg dose
- Median rPFS: 6.3 months overall; 8.3 months at 900 mg dose
- Safety profile: Most common adverse events were asymptomatic QT prolongation (47%) and bradycardia (34%)
- Efficacy by prior treatment: Longer rPFS in chemotherapy-naive patients (16.5 months) versus those with prior chemotherapy (5.5 months)
- Mechanism: Dual AR degrader and antagonist, showing activity regardless of AR ligand-binding domain mutation status
Important Caveats
- The drug labels provided 2 are for maropitant citrate (an antiemetic for dogs), which is completely unrelated to prostate cancer treatment and appears to be an error in the evidence compilation
- NCT06067841 may be an ongoing trial without published results, or the trial identifier may need verification
- For current treatment decisions in mCRPC, refer to established guidelines 3 recommending ARPIs, PARPi (for BRCA1/2 alterations), chemotherapy, or radiopharmaceuticals based on prior treatment history
To obtain actual results for NCT06067841, check ClinicalTrials.gov directly or contact the trial sponsor for any available data.